Recently, the U.S. Food and Drug Administration (FDA) approved Trikafta (elexacaftor/tezacaftor/ivacaftor) for the treatment of CF in people aged 12 years and older who have at least one F508del mutation in the CFTR gene. The gene discussed is CFTR; the disease is cystic fibrosis.